That is a very painful side effect. Is it possible that this side effect masks itself as verbal flatulence among those affected by it?
MNKD cancels critical CC and has no backup plan to support PPS.
It is so improbable that this has to fiction and not reality. I'm long but I'm beginning to think that this has become an "intentional Fiasco". All these displays of incompetence just can't be accidental. MNKD is second only to SNY in its quest to destroy Afrezza. I'm long but it is beginning to get very painful.
I think that most of his followers are aliases that he created to make himself appear legitimate.
What a pitiful creature he is!
Zero cost for manufacturing aliases and FUD....... aside from .05 a post. Perhaps that's where GS lost most of its money. Maybe they should fire half of their Fudsters. This bunch is a sorry lot of amatures.
When you start moving in the right direction you can only estimate at what speed you will be traveling. You can be absolutely certain of the direction. THe days of the French Sabotage are over.
When asked what a DTC campaign might look like, Castagna said planning has just begun. However, he did say, "This is about freedom for patients and them controlling their life as opposed to diabetes controlling their life. It's about bringing about that insight."
"I don't think telling people who are on insulin, 'Hey, try this' is going to work," Castagna went on to say. "I know people would say it's a no-brainer--it's inhaled versus an injection--but you've got to have that emotional connection that people are dealing with this disease every single day."
MannKind will maintain a consumer website in the meantime, he said, and may do some targeted direct-to-patient communications in larger markets that already have a core group of doctors and patients who understand the product.
Diabetes educators will play a role as well. Usually nurses, they will be employed by MannKind, Castagna said, and work similarly to medical science liaisons. Insurance companies are also important, he said, noting that MannKind is already working to remove managed care barriers and he is pleased with the progress.
From " Fierce Pharma Marketing "
April 11, 2016 | By Beth Snyder Bulik
23 posts | Last Activity: 1 minute 24 seconds ago
Member since: Apr 5, 2016
It's always amazing how bashers on the board for less than 4 days can have insight into a comany that is more secretive than the CIA.
Perhaps you can tell us What North Korea will do tomorrow!
Off to Ignore...
I'm interested in Matt's response or reaction. To know your enemy gives you weapons to fight him and the possibility of finding allies. One would hope that the BOD of MNKD are willing to fight for the success of what Al Mann devoted his life. Matt are you listening?
With less than 2 million shares traded today it's likely that much of this is MM pitch and catch or day traders. If longs and institutions were selling the volume would be significantly higher. Someone, probably an altruistic basher, wants you to sell. The bottom line is Sell or Buy according to criteria you establish. This usually begins with DD on the company and insight into how the market works. ( It isn't a kindergarden play group )
Sanofi spent $3.75 million on Afrezza advertising during the third quarter of 2015. During the same period, the treatment generated only about $2 million in revenue, according to data from Kantar Media. The “Surprise, it's Insulin!” campaign, which was developed by Havas Health, primarily targeted patients in the early stages of a diagnosis with type 2 diabetes.
Still, Pfeffer viewed Sanofi's strategy as flawed and said it failed to include potential patient populations. “They ignored segments, like type 1,” he said. “We think that was a mistake
What MannKind found in its own research was an active, aggressive group of patients with type 1 diabetes. Many of these patients were using continuous glucose monitoring systems and reporting online that they had had success with Afrezza. T. (For type 1 patients, the mealtime insulin must be taken in combination with long-acting insulin. Type 2 patients can use the product as a standalone therapy.)
Afrezza is the only FDA-approved inhaled insulin on the market. Pfizer, notably, scrapped its inhaled insulin product because it struggled to generate enough prescriptions and sales.
Pfeffer said the company plans to use direct-to-consumer advertising to promote Afrezza, but noted that the effort will be more focused and more cost-effective than the one launched by Sanofi. “What form that takes is still being determined,” he said. “That needs to be a little more targeted.”
MannKind is scheduled to report its first-quarter earnings in May and is expected to present four abstracts at the upcoming American Diabetes Association scientific meeting in June. It plans to use those events as platforms to explain and promote its new plans to market the insulin, Pfeffer said. Once its own marketing strategy is established, MannKind may consider partnering with another organization.
“We're not going to hand over the product to another pharma company,” Pfeffer said.
What will happen remains to be seen. But the truth is that diabetes is the major disease affecting mankind. It will get worse. A growing portion of healtcare dollars will be going into the treatment of diabetes.
By James Gallagher Health editor, BBC News website
The world is facing an "unrelenting march" of diabetes which now affects nearly one in 11 adults, the World Health Organization (WHO) says.
In a major report it warned cases had nearly quadrupled to 422 million in 2014 from 108 million in 1980.
High blood sugar levels are a major killer - linked to 3.7 million deaths around the world each year, it says.
And officials said the numbers would continue to increase unless "drastic action" was taken.
The report lumps both type 1 and type 2 diabetes together, but the surge in cases is predominantly down to type 2 - the form closely linked to poor lifestyle.
As the world's waistlines have ballooned - with one-in-three people now overweight, so too has the number of diabetes cases.
Read the full article in BBC news.
Diabetes: It's here, it's real and it's getting worse.
The question is how will MNKD position itself.
Salaries not salaroes....
It seems the mm's feeding the bears have only enough meat for 30 minutes. At around 10 am if it seems that they have not pushed the pps down enough to cause selling they are recalled. This may indicate that the powers that be might be getting ready to move on from MNKD. SA is desperately trying to collect a few pesos extra for those amateurish bash pieces yesterday and today.
Presently down .36% Nasdaq down .46%.
No selling so mm's are playing pitch and catch. Every time they try to bring it down a buyer intercepts the pitch and shares become "real". This can become very expensive for those who are financing this game. They may have to cut the salaroes of the paid bashers and fudsters if things don't improve substantially.
( sung to the tune of " How much wood would....." )
Tongue and marketing twister.
How many sandbags can Sanofi sandbagger bag
when Sanofi sandbagger bags sand....
That's a lot of Sanofi Sandbags since " Their " launch
Tomorrow they come down and the beach belongs to Mannkind
I don't think that there will be shares available tomorrow. SA and Fool better be working on some major hit pieces. Fudsters getting overly repetitious.